Table 3.
Possible reasons for the success of REFLECT trial
- Good trial design |
Weight-based dosing (12 vs. 8 mg) |
Noninferiority trial design |
- Potent anticancer activity over sorafenib |
- Acceptable toxicity |
- Longer treatment duration due to better tolerability, especially less hand-foot-skin reaction (5.7 vs. 3.7 months) |